Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      SynKIR-310 for Relapsed/Refractory B-NHL
      Description

      This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

      Conditions
      B Cell LymphomaNHL, AdultMantle Cell LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaAggressive B-Cell Non-Hodgkin LymphomaIndolent B-Cell Non-Hodgkin LymphomaFollicular LymphomaMarginal Zone LymphomaDLBCL - Diffuse Large B Cell LymphomaHGBL with MYC and BCL2 And/or BCL6 RearrangementsHigh-grade B-cell LymphomaDiffuse Large B Cell LymphomaLarge B-cell LymphomaT-Cell/Histiocyte Rich LymphomaNon-hodgkin Lymphoma,B CellPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Epstein-Barr Virus Positive DLBCL, NosFollicular Lymphoma Grade 3BDLBCL (Diffuse Large B-Cell Lymphoma) Associated with Chronic InflammationHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedFollicular Lymphoma Grade 3Marginal Zone Splenic LymphomaDLBCL
      Talk to us
      COMPLETED
      Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
      Description

      To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) chemotherapy in patients who have previously untreated ABC type DLBCL.

      Conditions
      Lymphoma, Large B-Cell, Diffuse
      Talk to us
      COMPLETED
      Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
      Description

      The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).

      Conditions
      B-cell Non-Hodgkins LymphomaChronic Lymphocytic Leukemia
      Talk to us